105
Participants
Start Date
November 6, 2019
Primary Completion Date
August 21, 2020
Study Completion Date
August 31, 2020
Drug: SHR0302
The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
Sun. Yat- Sen Memorial Hospital, Sun. Yat- Sen University, Guangzhou
Xuanwu Hospital Capital Medical University, Beijing
Peking University Third Hospital, Beijing
Peking union medical college hospital, Beijing
Beijing Tsinghua Changgeng Hospital, Beijing
The first hospital of China medical university, Shenyang
Shanghai Skin Disease Hospital, Shanghai
The First Affiliated Hospital of Soochow University, Suzhou
Jinan Central Hospital, Jinan
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin
The first affiliated hospital Zhejiang university, Hangzhou
Affiliated Hangzhou first people's hospital, Zhejiang university school of medicine, Hangzhou
Zhejiang province People's Hospital, Hangzhou
The First Affiliated Hospital of Fujian Medical University, Fuzhou
Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing
The Second Xiangya Hospital of Central South University, Changsha
Xiangya Hospital of Central South University, Changsha
The Third Xiangya Hospital of Central South University, Changsha
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Henan provincial people's hospital, Zhengzhou
Guangdong Provincial People's Hospital, Guangzhou
Peking University People's Hospital, Xicheng
The First Hospital of Shanxi Medical University, Taiyuan
Reistone Biopharma Company Limited
INDUSTRY